M
Maria H. Berrocal
Researcher at University of Puerto Rico
Publications - 98
Citations - 4030
Maria H. Berrocal is an academic researcher from University of Puerto Rico. The author has contributed to research in topics: Diabetic retinopathy & Visual acuity. The author has an hindex of 31, co-authored 94 publications receiving 3646 citations. Previous affiliations of Maria H. Berrocal include Bahçeşehir University & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Lihteh Wu,Maria Ana Martinez-Castellanos,Hugo Quiroz-Mercado,J. Fernando Arevalo,Maria H. Berrocal,Michel Eid Farah,Mauricio Maia,Jose A. Roca,Francisco Rodríguez +8 more
TL;DR: Repeated intravitreal injections of either 1.25 mg or 2.5 mg of bevacizumab appears to be safe and well tolerated during the 1st year despite the limited follow-up, according to this retrospective, multicenter, open label, uncontrolled interventional case series.
Journal ArticleDOI
Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy.
J.F. Arevalo,Mauricio Maia,Harry W. Flynn,Mario Saravia,Robert L. Avery,L. Wu,M. Eid Farah,Dante J. Pieramici,Maria H. Berrocal,Juan G. Sanchez +9 more
TL;DR: TRD may occur or progress shortly following administration of intravitreal bevacizumab in patients with severe PDR, a statistically significant improvement compared with TRD BCVA.
Journal ArticleDOI
Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
J. Fernando Arevalo,Jans Fromow-Guerra,Hugo Quiroz-Mercado,Juan G. Sanchez,Lihteh Wu,Mauricio Maia,Maria H. Berrocal,A. Solis-Vivanco,Michel Eid Farah +8 more
TL;DR: Primary intravitreal bevacizumab at doses of 1.25 to 2.5 mg seem to provide stability or improvement in VA, OCT, and FA in DME at 6 months, and results appear promising.
Journal Article
Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema: Results of the Pan-American Collaborative Retina Study Group at 6-Months Follow-Up
J.F. Arevalo,Jans Fromow-Guerra,Hugo Quiroz-Mercado,Juan G. Sanchez,L. Wu,Mauricio Maia,Maria H. Berrocal,A. Solis-Vivanco,Michel Eid Farah +8 more
Journal ArticleDOI
Variations in the Clinical Course of Submacular Hemorrhage
TL;DR: Patients with submacular hemorrhage may have spontaneous improvement in visual acuity without surgery, and patients without subretinal neovascular membranes had a better visual improvement rate.